JOURNEY MEDICAL CORP (DERM) Fundamental Analysis & Valuation

NASDAQ:DERM • US48115J1097

Current stock price

7.02 USD
+0.39 (+5.88%)
Last:

This DERM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. DERM Profitability Analysis

1.1 Basic Checks

  • In the past year DERM has reported negative net income.
  • DERM had a negative operating cash flow in the past year.
  • In the past 5 years DERM reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: DERM reported negative operating cash flow in multiple years.
DERM Yearly Net Income VS EBIT VS OCF VS FCFDERM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • DERM has a better Return On Assets (-10.17%) than 67.88% of its industry peers.
  • The Return On Equity of DERM (-33.45%) is better than 61.66% of its industry peers.
Industry RankSector Rank
ROA -10.17%
ROE -33.45%
ROIC N/A
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
DERM Yearly ROA, ROE, ROICDERM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

  • Looking at the Gross Margin, with a value of 64.40%, DERM is in the better half of the industry, outperforming 72.54% of the companies in the same industry.
  • DERM's Gross Margin has declined in the last couple of years.
  • DERM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
DERM Yearly Profit, Operating, Gross MarginsDERM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. DERM Health Analysis

2.1 Basic Checks

  • DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DERM has been increased compared to 1 year ago.
  • Compared to 5 years ago, DERM has more shares outstanding
  • Compared to 1 year ago, DERM has a worse debt to assets ratio.
DERM Yearly Shares OutstandingDERM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DERM Yearly Total Debt VS Total AssetsDERM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of 0.77, we must say that DERM is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of DERM (0.77) is comparable to the rest of the industry.
  • DERM has a Debt/Equity ratio of 0.75. This is a neutral value indicating DERM is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.75, DERM is doing worse than 67.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Altman-Z 0.77
ROIC/WACCN/A
WACC9.61%
DERM Yearly LT Debt VS Equity VS FCFDERM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • A Current Ratio of 1.42 indicates that DERM should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.42, DERM is doing worse than 72.54% of the companies in the same industry.
  • DERM has a Quick Ratio of 1.12. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.12, DERM is doing worse than 73.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.12
DERM Yearly Current Assets VS Current LiabilitesDERM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. DERM Growth Analysis

3.1 Past

  • DERM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.41%, which is quite impressive.
  • DERM shows a small growth in Revenue. In the last year, the Revenue has grown by 2.82%.
  • DERM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.96% yearly.
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
Revenue 1Y (TTM)2.82%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.52%

3.2 Future

  • DERM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.50% yearly.
  • The Revenue is expected to grow by 39.53% on average over the next years. This is a very strong growth
EPS Next Y52%
EPS Next 2Y50.08%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue Next Year13.98%
Revenue Next 2Y33.27%
Revenue Next 3Y39.53%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DERM Yearly Revenue VS EstimatesDERM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
DERM Yearly EPS VS EstimatesDERM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. DERM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DERM. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 27.26, the valuation of DERM can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DERM indicates a somewhat cheap valuation: DERM is cheaper than 74.09% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.42. DERM is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 27.26
DERM Price Earnings VS Forward Price EarningsDERM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DERM Per share dataDERM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as DERM's earnings are expected to grow with 48.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.08%
EPS Next 3Y48.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DERM Dividend Analysis

5.1 Amount

  • No dividends for DERM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DERM Fundamentals: All Metrics, Ratios and Statistics

JOURNEY MEDICAL CORP

NASDAQ:DERM (3/23/2026, 3:49:04 PM)

7.02

+0.39 (+5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-25
Inst Owners39.39%
Inst Owner Change26.67%
Ins Owners12.01%
Ins Owner Change0%
Market Cap191.37M
Revenue(TTM)59.40M
Net Income(TTM)-8.66M
Analysts82
Price Target13.77 (96.15%)
Short Float %12.61%
Short Ratio21.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-67.58%
Min EPS beat(2)-85.76%
Max EPS beat(2)-49.39%
EPS beat(4)2
Avg EPS beat(4)-12.79%
Min EPS beat(4)-85.76%
Max EPS beat(4)58.28%
EPS beat(8)2
Avg EPS beat(8)-31.88%
EPS beat(12)4
Avg EPS beat(12)26.25%
EPS beat(16)5
Avg EPS beat(16)-0.28%
Revenue beat(2)0
Avg Revenue beat(2)-4.89%
Min Revenue beat(2)-8.32%
Max Revenue beat(2)-1.46%
Revenue beat(4)1
Avg Revenue beat(4)-2.25%
Min Revenue beat(4)-8.32%
Max Revenue beat(4)6.86%
Revenue beat(8)2
Avg Revenue beat(8)-1.81%
Revenue beat(12)4
Avg Revenue beat(12)5.69%
Revenue beat(16)5
Avg Revenue beat(16)1.83%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-27.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.26
P/S 3.22
P/FCF N/A
P/OCF N/A
P/B 7.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)0.26
Fwd EY3.67%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS2.18
BVpS0.95
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.17%
ROE -33.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.4%
FCFM N/A
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
F-Score5
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 1.12
Altman-Z 0.77
F-Score5
WACC9.61%
ROIC/WACCN/A
Cap/Depr(3y)346.04%
Cap/Depr(5y)304.38%
Cap/Sales(3y)20.06%
Cap/Sales(5y)15.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
EPS Next Y52%
EPS Next 2Y50.08%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue 1Y (TTM)2.82%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.52%
Revenue Next Year13.98%
Revenue Next 2Y33.27%
Revenue Next 3Y39.53%
Revenue Next 5YN/A
EBIT growth 1Y44.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.72%
EBIT Next 3Y84.38%
EBIT Next 5YN/A
FCF growth 1Y-246.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.93%
OCF growth 3YN/A
OCF growth 5YN/A

JOURNEY MEDICAL CORP / DERM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of JOURNEY MEDICAL CORP (DERM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DERM.


Can you provide the valuation status for JOURNEY MEDICAL CORP?

ChartMill assigns a valuation rating of 3 / 10 to JOURNEY MEDICAL CORP (DERM). This can be considered as Overvalued.


What is the profitability of DERM stock?

JOURNEY MEDICAL CORP (DERM) has a profitability rating of 2 / 10.